Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Takeda Pharmaceutical Ltd ADR
(NY:
TAK
)
13.22
-0.09 (-0.68%)
Official Closing Price
Updated: 7:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Takeda Pharmaceutical Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum
February 03, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)
January 31, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Named Global Top Employer for Fifth Consecutive Year
January 19, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Celebrates World Quality Week
November 10, 2021
SOURCE: Takeda
Via
3BL Media
Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference
January 10, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
January 10, 2022
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Complete Response Letter from the U.S. FDA for TAK-721
December 21, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Systemic Mastocytosis Treatments Gain Hope Due To Increasing Novel Treatment Options
December 21, 2021
Palm Beach, FL –December 21, 2021 – FinancialNewsMedia.com News Commentary – Systemic mastocytosis is rare disease which affects very few people and it causes due to C-kit mutation which leads to...
Via
FinancialNewsMedia
Exposures
Product Safety
Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
December 13, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)
December 08, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Unveils New Research to Advance Patient Care in Hematology and Oncology at 63rd American Society of Hematology (ASH) Annual Meeting
December 07, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s LIVTENCITY™ (maribavir) Now Available for Certain Individuals Ages 12 Years and Older With Post-Transplant Cytomegalovirus (CMV) Infection/Disease in the United States
December 02, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces U.S. Corporate Social Responsibility (CSR) Program Aimed to Help Reduce Social Disparities
November 30, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda’s LIVTENCITYTM (maribavir) Approved by U.S. FDA as the First and Only Treatment for People Ages 12 and Older with Post-Transplant Cytomegalovirus (CMV), Refractory (With or Without Genotypic Resistance) to Conventional Antiviral Therapies
November 23, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Applied for Selection of “Prime Market”, Filed Corporate Governance Report With Tokyo Stock Exchange (TSE) in Line With Revised Corporate Governance Code and Published Corporate Governance Related Documents on its Website
November 01, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Recommends Common-sense Policy Reforms Designed to Reduce Time to Diagnosis, Improve Access to Care for Patients with Rare Disease
November 04, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces Acquisition of Own Shares
October 28, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Delivers Strong H1 FY2021 Results; Further Growth Momentum Expected Through Fiscal Year-End Driven by 14 Global Brands
October 28, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors
October 27, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
BioLife Plasma Services Announces Expansion of Plasma Donation Centers into Massachusetts
October 13, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Advisory Committee Recommends Use of Investigational Drug Maribavir (TAK-620) to Treat Post-Transplant Recipients with Cytomegalovirus (CMV) Infection and Disease Refractory to Treatment With or Without Resistance
October 07, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Provides Update on TAK-994 Clinical Program
October 05, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda to Commercialize Next-Generation Hunter Syndrome Therapy Through Collaboration with JCR Pharmaceuticals
September 30, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Selects Four New Partners for Annual Global Corporate Social Responsibility (CSR) Program to Help Strengthen Health Systems in Low- and Middle-Income Countries
September 22, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
September 21, 2021
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
September 15, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial
September 01, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
BioLife Plasma Services Opens First All-Electric Plasma Donation Center
August 18, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Final Results from the Longest Hereditary Angioedema Study of Active Treatment Duration Conducted to Date Support the Sustained Safety and Efficacy of TAKHZYRO® (lanadelumab) Injection for Long-Term Prevention of Hereditary Angioedema Attacks
August 05, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie
August 01, 2021
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.